Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 (Screening).~* Ability to follow study instructions, complete study assessment tools with minimal assistance and no alteration to the assessment tools, and likely to complete all required visits.~* Participant meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for schizophrenia as determined by Structured Clinical Interview for DSM-5 (SCID-5).~* Positive and Negative Syndrome Scale (PANSS) total score \>= 70 and \<= 120 at Visit 1 and Visit 2 (Day 1).~* Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms; P1: delusions; P2: conceptual disorganization; P3: hallucinatory behaviour; P6: suspiciousness/persecution at Visit 1 and Visit 2.~Exclusion Criteria:~* Currently meeting DSM-5 criteria for any of the following:~* Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders~* Bipolar I and II disorder~* Autism spectrum disorder, intellectual development disorder, delirium, major/minor neurocognitive disorder~* History of meeting DSM-5 criteria for substance-related disorders (excluding caffeine-related and tobacco-related disorders) within the prior 3 months before Visit 1.~* Prior participation in any clinical trials involving experimental or investigational drugs within 6 months before Visit 1 or planned during the study.~* Female Participants who are pregnant, planning to become pregnant during the course of the study, or are currently lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine 4.5 mg/day (Open-label Treatment Period) (Type: EXPERIMENTAL): Cariprazine 1.5 mg capsules orally once daily at Week 1, titrated to 3.0 mg capsules orally once daily at Week 2 and then titrated to 4.5 mg orally once daily from Week 3 through Week 18 in the Open-label Treatment Period.
- Placebo (Double-blind Treatment Period) (Type: PLACEBO_COMPARATOR): Cariprazine placebo-matching capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
- Cariprazine 3.0 mg/day (Double-blind Treatment Period) (Type: EXPERIMENTAL): Cariprazine 3.0 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
- Cariprazine 4.5 mg/day (Double-blind Treatment Period) (Type: EXPERIMENTAL): Cariprazine 4.5 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).